MicroRNAs in cancer: Personalizing diagnosis and therapy

Annals of the New York Academy of Sciences

Volumn 1210, Issue 1, 2010, Pages 25-33

  Nana Sinkam, S Patrick ^a,b   Fabbri, Muller ^a,b   Croce, Carlo M ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cancer; Genome; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 155; MICRORNA 21; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DEREGULATION; DIAGNOSTIC TEST; GENE EXPRESSION; GENE REGULATORY NETWORK; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LIVER CANCER; LUNG CANCER; NEOPLASM; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERSONALIZED MEDICINE; PROGNOSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SOLID TUMOR; SPAIN; ACUTE GRANULOCYTIC LEUKEMIA; BLOOD DISEASE; BREAST TUMOR; COLORECTAL TUMOR; DOWN REGULATION; FEMALE; GENETICS; LUNG TUMOR; METHODOLOGY; PANCREAS TUMOR; UPREGULATION;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; LUNG NEOPLASMS; MICRORNAS; NEOPLASMS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; UP-REGULATION;

EID: 78349239295     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05822.x     Document Type: Article

References (79)

1. International Agency for Research on Cancer. GLOBOCAN 2008.
2. Lee, R.C., R.L. Feinbaum & V. Ambros 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854.
3. Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
4. Croce, C.M. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10: 704-714.
5. Calin, G.A., M. Ferracin, A. Cimmino, et al 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353: 1793-1801.
6. Pekarsky, Y., U. Santanam, A. Cimmino, et al 2006. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66: 11590-11593.
7. Venturini, L., K. Battmer, M. Castoldi, et al 2007. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 109: 4399-4405.
8. Bueno, M.J., I. Perez de Castro, M. Gomez de Cedron, et al 2008. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496-506.
9. Agirre, X., A. Jimenez-Velasco, E. San Jose-Eneriz, et al 2008. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res. 6: 1830-1840.
10. Zanette, D.L., F. Rivadavia, G.A. Molfetta, et al 2007. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 40: 1435-1440.
11. Agirre, X., A. Vilas-Zornoza, A. Jimenez-Velasco, et al 2009. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69: 4443-4453.
12. Garzon, R., M. Garofalo, M.P. Martelli, et al 2008. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl. Acad. Sci. USA 105: 3945-3950.
13. Marcucci, G., M.D. Radmacher, K. Maharry, et al 2008. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358: 1919-1928.
14. Garzon, R., S. Volinia, C.G. Liu, et al 2008. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183-3189.
15. Mi, S., J. Lu, M. Sun, et al 2007. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 104: 19971-19976.
16. Roehle, A., K.P. Hoefig, D. Repsilber, et al 2008. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br. J. Haematol. 142: 732-744.
17. Eis, P.S., W. Tam, L. Sun, et al 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 102: 3627-3632.
18. Lawrie, C.H., S. Soneji, T. Marafioti, et al 2007. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer. 121: 1156-1161.
19. Rosenwald, A., G. Wright, K. Leroy, et al 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198: 851-862.
20. Navarro, A., A. Gaya, A. Martinez, et al 2008. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 111: 2825-2832.
21. Van Vlierberghe, P., A. De Weer, P. Mestdagh, et al 2009. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br. J. Haematol. 147: 686-690.
22. Navarro, A., T. Diaz, A. Martinez, et al 2009. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114: 2945-2951.
23. Fabbri, M., R. Spizzo & G.A. Calin 2010. High-throughput profiling in the hematopoietic system. Methods Mol. Biol. 667: 79-91.
24. Fabbri, M. 2010. miRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 10: 435-444.
25. Calin, G.A., R. Garzon, A. Cimmino, et al 2006. MicroRNAs and leukemias: how strong is the connection. Leuk. Res. 30: 653-655.
26. Call, T.G., R.L. Phyliky, P. Noel, et al 1994. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin. Proc. 69: 323-328.
27. Chiorazzi, N., K.R. Rai & M. Ferrarini 2005. Chronic lymphocytic leukemia. N. Engl. J. Med. 352: 804-815.
28. Calin, G.A., C.D. Dumitru, M. Shimizu, et al 2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99: 15524-15529.
29. Cimmino, A., G.A. Calin, M. Fabbri, et al 2005. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102: 13944-13949.
30. Calin, G.A., A. Cimmino, M. Fabbri, et al 2008. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA 105: 5166-5171.
31. Pekarsky, Y., N. Zanesi, R.I. Aqeilan & C.M. Croce 2007. Animal models for chronic lymphocytic leukemia. J. Cell Biochem. 100: 1109-1118.
32. Raveche, E.S. 1990. Possible immunoregulatory role for CD5 + B cells. Clin. Immunol. Immunopathol. 56: 135-150.
33. Raveche, E.S., E. Salerno, B.J. Scaglione, et al 2007. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109: 5079-5086.
34. Klein, U., M. Lia, M. Crespo, et al 2010. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
35. Liu, Y., M. Corcoran, O. Rasool, et al 1997. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 15: 2463-2473.
36. Migliazza, A., F. Bosch, H. Komatsu, et al 2001. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 97: 2098-2104.
37. Salerno, E., B.J. Scaglione, F.D. Coffman, et al 2009. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol. Cancer Ther. 8: 2684-2692.
38. He, L., J.M. Thomson, M.T. Hemann, et al 2005. A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
39. Ota, A., H. Tagawa, S. Karnan, et al 2004. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 64: 3087-3095.
40. Xiao, C., L. Srinivasan, D.P. Calado, et al 2008. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat. Immunol. 9: 405-414.
41. Ventura, A., A.G. Young, M.M. Winslow, et al 2008. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132: 875-886.
42. Olive, V., M.J. Bennett, J.C. Walker, et al 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 23: 2839-2849.
43. Mu, P., Y.C. Han, D. Betel, et al 2009. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 23: 2806-2811.
44. Volinia, S., G.A. Calin, C.G. Liu, et al 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103: 2257-2261.
45. Calin, G.A., C.M. Croce 2007. Investigation of microRNA alterations in leukemias and lymphomas. Methods Enzymol. 427: 193-213.
46. Marton, S., M.R. Garcia, C. Robello, et al 2008. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22: 330-338.
47. Metzler, M., M. Wilda, K. Busch, et al 2004. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39: 167-169.
48. Kluiver, J., S. Poppema, D. de Jong, et al 2005. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 207: 243-249.
49. Nie, K., M. Gomez, P. Landgraf, et al 2008. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am. J. Pathol. 173: 242-252.
50. Costinean, S., N. Zanesi, Y. Pekarsky, et al 2006. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. USA 103: 7024-7029.
51. Costinean, S., S.K. Sandhu, I.M. Pedersen, et al 2009. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 114: 1374-1382.
52. Thai, T.H., D.P. Calado, S. Casola, et al 2007. Regulation of the germinal center response by microRNA-155. Science 316: 604-608.
53. Rodriguez, A., E. Vigorito & S. Clare 2007. Requirement of bic/microRNA-155 for normal immune function. Science 316: 608-611.
54. Cummins, J.M., Y. He, R.J. Leary, et al 2006. The colorectal microRNAome. Proc. Natl. Acad. Sci. USA 103: 3687-3692.
55. Akao, Y., Y. Nakagawa & T. Naoe 2007. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 26: 311-320.
56. Slaby, O., M. Svoboda, P. Fabian, et al 2007. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402.
57. Lanza, G., M. Ferracin, R. Gafa, et al 2007. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 6: 1-11.
58. Valeri, N., P. Gasparini, M. Fabbri, et al 2010. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl. Acad. Sci. USA 107: 6982-6987.
59. Chen, X., Y. Ba, L. Ma, et al 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18: 997-1006.
60. Ng, E.K., W.W. Chong, H. Jin, et al 2009. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58: 1375-1381.
61. Bloomston, M., W.L. Frankel, F. Petrocca, et al 2007. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
62. Szafranska, A.E., T.S. Davison, J. John, et al 2007. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452.
63. Szafranska, A.E., M. Doleshal, H.S. Edmunds, et al 2008. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin. Chem. 54: 1716-1724.
64. Giovannetti, E., N. Funel, G.J. Peters, et al 2010. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70: 4528-4538.
65. Hwang, J.H., J. Voortman, E. Giovannetti, et al 2010. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 5: 1-12.
66. Jemal, A., R. Siegel, J. Xu & E. Ward 2010. Cancer Statistics 2010. CA Cancer J. Clin. 60: 277-300.
67. Yanaihara, N., N. Caplen, E. Bowman, et al 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9: 189-198.
68. Yu, S.L., H.Y. Chen, G.C. Chang, et al 2008. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 13: 48-57.
69. Fabbri, M., R. Garzon, A. Cimmino, et al 2007. MicroRNA-29 family reverts aberrent methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 104: 15805-15810.
70. Garofalo, M., G. Di Leva, G. Romano, et al 2009. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 16: 498-509.
71. Kumar, M.S., S.J. Erkeland, R.E. Pester, et al 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 105: 3903-3908.
72. Johnson, S.M., H. Grosshans, J. Shingara, et al 2005. RAS is regulated by the let-7 microRNA family. Cell. 120: 635-647.
73. Iorio, M.V., M. Ferracin, C.G. Liu, et al 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65: 7065-7070.
74. Spizzo, R., M.S. Nicoloso, L. Lupini, et al 2010. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 17: 246-254.
75. Sachdeva, M. & Y.Y. Mo 2010. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70: 378-387.
76. Faraoni, I., F.R. Antoinetti, J. Cardone, et al 2009. miR-155 gene: a typical multifactorial microRNA. Biochem. Biophys. Acta. 1792: 497-505.
77. Kong, W., L. He, M. Coppola, et al 2010. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 285: 17869-17879.
78. Jiang, S., H.W. Zhang, M.H. Lu, et al 2010. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70: 3119-3127.
79. Volinia, S., M. Galasso, S. Costinean, et al 2010. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20: 589-599.